Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
Trial ID or NCT#
NCT01020812
Status
NOT RECRUITING
Purpose
To determine the efficacy and toxicity of TACE combined with SBRT
Official Title
Phase II Study of Combination Stereotactic Body Radiotherapy (SBRT) With Transarterial Chemo-Embolization (TACE) for Unresectable Hepatocellular Carcinoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Daniel Chang
Brendan C. Visser, MD
Hepatobiliary surgeon,
Pancreatic surgeon
Associate Professor of Surgery (General Surgery)
Samuel So, MD
Surgical oncologist,
Liver surgeon,
General surgeon
Lui Hac Minh Professor in the School of Medicine
George A. Fisher Jr.
Medical oncologist,
Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Lawrence "Rusty" Hofmann, MD
Interventional radiologist
Professor of Radiology (Interventional Radiology)
Contact us to find out if this trial is right for you.
Contact
ccto-office@stanford.edu
650-498-7061
View on ClinicalTrials.gov